PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT2594901

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
SYSTAGENIX WOUND MANAGEMENT (US), INC.	10/28/2013

RECEIVING PARTY DATA

Name:	BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Street Address:	ONE INDEPENDENCE CENTER
Internal Address:	101 N. TRYON ST.: MAIL CODE NC1-001-05-45
City:	CHARLOTTE
State/Country:	NORTH CAROLINA
Postal Code:	28255-0001

PROPERTY NUMBERS Total: 78

Property Type	Number
Application Number:	12373619
Application Number:	12516487
Application Number:	13146553
Application Number:	13318938
Application Number:	13224647
Application Number:	12677236
Application Number:	12643644
Patent Number:	D429630
Patent Number:	D447710
Patent Number:	D458687
Patent Number:	D557424
Application Number:	10528262
Application Number:	10529157
Application Number:	10538427
	DATENT

Application Number:	10560544
Application Number:	10579897
Application Number:	10587993
Application Number:	11477307
Application Number:	11516210
Application Number:	11575412
Application Number:	11608906
Application Number:	11608940
Application Number:	11609964
Application Number:	10502882
Application Number:	10543554
Application Number:	10576633
Application Number:	10576634
Application Number:	11814807
Application Number:	12160610
Application Number:	12279346
Application Number:	13377071
Patent Number:	5447940
Patent Number:	5571529
Patent Number:	5660857
Patent Number:	5688522
Patent Number:	5693624
Patent Number:	5700476
Patent Number:	5705485
Patent Number:	5723144
Patent Number:	5735812
Patent Number:	5749842
Patent Number:	5766631
Patent Number:	5789465
Patent Number:	5888987
Patent Number:	5912114
Patent Number:	5981822
Patent Number:	6001895
Patent Number:	6015844
Patent Number:	6019996
r	PATENT

	6022556
Patent Number:	6050967
Patent Number:	6166084
Patent Number:	6326410
Patent Number:	6440940
Patent Number:	6509388
Patent Number:	6566577
Patent Number:	6638909
Patent Number:	6713083
Patent Number:	6915950
Patent Number:	7361634
Patent Number:	7538257
Patent Number:	7566564
Patent Number:	7601546
Patent Number:	7732655
Patent Number:	7772454
Patent Number:	7794925
Patent Number:	7955572
Patent Number:	8012698
Patent Number:	8058499
Patent Number:	8063052
Patent Number:	8067370
Patent Number:	8097272
Patent Number:	8124370
Patent Number:	8124826
Patent Number:	8377651
Patent Number:	8481801
Patent Number:	8491852
Patent Number:	8541193

CORRESPONDENCE DATA

Fax Number:

Email: michael.barys@thomsonreuters.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: ELAINE CARRERA, LEGAL ASSISTANT Address Line 1: C/O CAHILL GORDON & REINDEL LLP

PATENT

REEL: 031508 FRAME: 0013

Address Line 2: 80 PINE S Address Line 4: NEW YOR	STREET RK, NEW YORK 10005
NAME OF SUBMITTER:	ELAINE CARRERA
Signature:	/Michael Barys TR/
Date:	10/29/2013
source=Intellectual Property Patent Securi	ty Agreement Supplement_ KCI (EXECUTED)_#page1.tif ty Agreement Supplement_ KCI (EXECUTED)_#page2.tif ty Agreement Supplement_ KCI (EXECUTED)_#page3.tif ty Agreement Supplement_ KCI (EXECUTED)_#page4.tif ty Agreement Supplement_ KCI (EXECUTED)_#page5.tif ty Agreement Supplement_ KCI (EXECUTED)_#page6.tif ty Agreement Supplement_ KCI (EXECUTED)_#page7.tif ty Agreement Supplement_ KCI (EXECUTED)_#page8.tif ty Agreement Supplement_ KCI (EXECUTED)_#page9.tif ty Agreement Supplement_ KCI (EXECUTED)_#page10.tif ty Agreement Supplement_ KCI (EXECUTED)_#page11.tif ty Agreement Supplement_ KCI (EXECUTED)_#page12.tif ty Agreement Supplement_ KCI (EXECUTED)_#page13.tif ty Agreement Supplement_ KCI (EXECUTED)_#page13.tif ty Agreement Supplement_ KCI (EXECUTED)_#page14.tif ty Agreement Supplement_ KCI (EXECUTED)_#page15.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT

SUPPLEMENT NO. 2 (this "**Supplement**") dated as of October 28, 2013, to the First Lien Intellectual Property Security Agreement dated as of November 4, 2011 among CHIRON MERGER SUB, INC., a Texas corporation (the "**Initial Borrower**"), KINETIC CONCEPTS, INC., a Texas corporation ("**Lead Borrower**"), and the other Persons listed on the signature pages hereof (collectively, the "**Initial Grantors**"), certain subsidiaries of the Company from time to time party hereto and BANK OF AMERICA, N.A. ("**BANA**"), as Collateral Agent for the Secured Parties.

- A. Reference is made to the credit agreement dated as of November 4, 2011 (as amended by Amendment No. 1 to Credit Agreement, dated as of November 7, 2012 and Amendment No. 2 to Credit Agreement, dated as of June 14, 2013, and as further amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), among the Initial Borrower, the Lead Borrower, CHIRON HOLDINGS, INC., a Delaware corporation ("Holdings"), CHIRON TOPCO, INC., a Delaware corporation ("Topco"), KCI USA, INC., a Delaware corporation ("KCI USA" and, together with the Lead Borrower, the "Co-Borrowers"), CENTAUR GUERNSEY LP, INC. ("Parent"), BANA, as administrative agent (in such capacity, the "Administrative Agent"), and collateral agent (in such capacity, the "Collateral Agent"), each Lender from time to time party thereto and the other parties party thereto, pursuant to which the Lenders have severally agreed to make Loans, the L/C Issuers to issue Letters of Credit to the Co-Borrowers and the Hedge Banks to enter into Secured Hedge Agreements upon the terms and subject to the conditions therein.
- B. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement and the Intellectual Property Security Agreement referred to therein.
- C. In connection with the Credit Agreement, the Co-Borrowers, Holdings and the other Grantors have entered into the Intellectual Property Security Agreement in order to induce the Lenders to make Loans, the L/C Issuers to issue Letters of Credit and the Hedge Banks to enter into Secured Hedge Agreements. Section 5.14 of the Intellectual Property Security Agreement provides that additional Material Subsidiaries may become Grantors under the Intellectual Property Security Agreement by execution and delivery of an instrument in the form of this Supplement. The undersigned Material Subsidiary (the "New Grantor") is executing this Supplement in accordance with the requirements of the Credit Agreement to become a Grantor under the Intellectual Property Security Agreement in order to induce the Lenders to make Loans, the L/C Issuers to issue Letters of Credit and the Hedge Banks to enter into Secured Hedge Agreements from time to time under the terms of the Credit Agreement.

Accordingly, the Collateral Agent and the New Grantor agree as follows:

SECTION 1. In accordance with Section 5.14 of the Intellectual Property Security Agreement, the New Grantor by its signature below becomes a Grantor under the Intellectual Property Security Agreement with the same force and effect as if originally named therein as a Grantor and the New Grantor hereby (a) agrees to all the terms and provisions of the Intellectual Property Security Agreement applicable to it as a Grantor thereunder and (b) represents and warrants that the representations and warranties made by it as a Grantor thereunder are true and correct on and as of the date hereof. In furtherance of the foregoing, the New Grantor, as security for the payment and performance in full of the Obligations does hereby create and grant to the Collateral Agent, its successors and assigns, for the benefit of the Secured Parties, their successors and assigns, a security interest in and lien on all of the New Grantor's right, title and interest in and to the Collateral (as defined in the

Intellectual Property Security Agreement) of the New Grantor. Each reference to a "Grantor' in the Intellectual Property Security Agreement shall be deemed to include the New Grantor. The Intellectual Property Security Agreement is hereby incorporated herein by reference.

- SECTION 2. The New Grantor represents and warrants to the Collateral Agent and the other Secured Parties that this Supplement has been duly authorized, executed and delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as such enforceability may be limited by Debtor Relief Laws and by general principles of equity.
- SECTION 3. This Supplement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Supplement shall become effective when the Collateral Agent shall have received a counterpart of this Supplement that bears the signature of the New Grantor, and the Collateral Agent has executed a counterpart hereof. Delivery of an executed signature page to this Supplement by facsimile transmission or other electronic communication (such as a ".pdf' or ".tif') shall be as effective as delivery of a manually signed counterpart of this Supplement.
- SECTION 4. The New Grantor hereby represents and warrants that (a) set forth on Schedule I attached hereto is a true and correct schedule of the Collateral and (b) set forth under its signature hereto is the true and correct legal name of the New Grantor, its jurisdiction of formation and the location of its chief executive office.
- SECTION 5. The Grantor hereby grants to the Collateral Agent for the ratable benefit of the Secured Parties a security interest in all of such Grantor's right, title and interest in and to the Collateral, including:
 - (a) the Patents (as defined in the Intellectual Property Security Agreement) set forth in Schedule I hereto;
 - (b) the registered Trademarks (as defined in the Intellectual Property Security Agreement) and Trademarks for which applications are pending set forth in Schedule I hereto; and
 - (c) the registrations of Copyrights (as defined in the Intellectual Property Security Agreement) and Copyrights for which applications are pending set forth in Schedule I hereto.
- SECTION 6. The grant of a security interest in the Collateral by the Grantor under this Supplement secures the payment of all Obligations of such Grantor now or hereafter existing under or in respect of the Loan Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. Without limiting the generality of the foregoing, this Supplement secures the payment of all amounts that constitute part of the secured Obligations and that would be owed by such Grantor to any Secured Party under the Loan Documents but for the fact that such secured Obligations are unenforceable or not allowable due to the existence of a bankruptcy, reorganization or similar proceeding involving a Loan Party.
- SECTION 7. <u>Grants, Rights and Remedies</u>. This Supplement has been entered into in conjunction with the provisions of the Intellectual Property Security Agreement. The New Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Intellectual Property Security Agreement, the terms and provisions of which are incorporated herein by reference as if

fully set forth herein. In the event of any conflict between the terms of this Supplement and the terms of the Intellectual Property Security Agreement, the terms of the Intellectual Property Security Agreement shall govern.

SECTION 8. The Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks and any other applicable government officer record this Supplement with respect to United States Patents, United States registered Trademarks and Trademarks for which United States applications are pending, and United States registered Copyrights listed in Schedule I(a) hereto.

SECTION 9. Except as expressly supplemented hereby, the Intellectual Property Security Agreement shall remain in full force and effect.

SECTION 10. THIS SUPPLEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

SECTION 11. In case any one or more of the provisions contained in this Supplement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and in the Intellectual Property Security Agreement shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties hereto shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.

SECTION 12. All communications and notices hereunder shall be in writing and given as provided in Section 5.01 of the Intellectual Property Security Agreement.

SECTION 13. Reimbursement of the Collateral Agent's expenses under this Supplement shall be governed by the applicable sections of the Intellectual Property Security Agreement.

[Remainder of Page Intentionally Blank]

IN WITNESS WHEREOF, the New Grantor and the Collateral Agent have duly executed this Supplement to the First Lien Intellectual Property Security Agreement as of the day and year first above written.

SYST	AGENIX WOUND MANAGEMENT (US) INC:
By:	//
¥	Name: Nathan P. Speicher
	Title: Vice President, Treasurer
Jurisd	iction of Formation: Delaware
Addre	ss Of Chief Executive Office:
	IH 10 West
San A	ntonio, Texas 78249
BANI	COF AMERICA, N.A.,
	Hateral Agent
eric enice	Warner v 20 200
Ву:	
	Name:
	Title:

BANK OF AMERICA, N.A.,

as Collateral Agent

By:

Name: Title: Anthony W. Kell Vice President

PATENT

REEL: 031508 FRAME: 0019

United States Intellectual Property

Patents:

			Serial No.	Patent No.
	Assignee	Patent title	Filing Date	Issue Date
1.	Systagenix Wound	Hydrogel wound dressings	12373619	
	Management (US), Inc.;	exhibiting reduced fiber	11/17/2009	
	Systagenix Wound	losses in use		
	Management IP Co. B.V.			
2.	Systagenix Wound	New wound dressing	12516487	
	Management (US), Inc.;	compositions	03/10/2010	
	Systagenix Wound			
	Management IP Co. B.V.			
3.	Systagenix Wound	Absorbent foam wound	13146553	
	Management (US), Inc.	dressing materials	12/12/2011	
4.	Systagenix Wound	Wound dressing materials	13318938	
	Management (US), Inc.		01/26/2012	
5.	Systagenix Wound	Treatment of diabetic	13224647	
	Management (US), Inc.	ulcers based on measuring	09/02/2011	
		the level of cytokine in		
		fluid or tissue from the		
	~	ulcer	10/5=00/	
6.	Systagenix Wound	Wound dressing with	12677236	
	Management (US), Inc.*	aperture cover sheet	08/04/2010	
7.	Systagenix Wound	Wound healing	12643644	
	Management (US), Inc.;		12/21/2009	
	Systagenix Wound			
8.	Management IP Co. B.V. Systagenix Wound	Containon with our	29104223	D429630
0.	Management (US), Inc.;	Container with cap	04/30/1999	08/22/2000
	Systagenix Wound		04/30/1999	08/22/2000
	Management IP Co. B.V.			
9.	Systagenix Wound	Wound dressing guide	29131881	D447710
٠.	Management (US), Inc.	wound dressing guide	10/30/2000	09/11/2001
10.	Systagenix Wound	Dressing	29139479	D458687
10.	Management (US), Inc.;	Diessing	03/29/2001	06/11/2002
	Systagenix Wound		03/23/2001	00/11/2002
	Management IP Co. B.V.			
11.	Systagenix Wound	Wound dressing	29228165	D557424
***	Management (US), Inc.;	Julia di Cooling	04/20/2005	12/11/2007
	Systagenix Wound		"	
	Management IP Co. B.V.			
12.	Systagenix Wound	Compositions for wound	10528262	
	Management (US), Inc.;	treatment	11/18/2005	
	Systagenix Wound			
	Management IP Co. B.V.			
13.	Systagenix Wound	Enzyme-sensitive	10529157	
	Management (US), Inc.;	therapeutic wound	10/13/2005	
	Systagenix Wound	dressings		
	Management IP Co. B.V.			

			Serial No.	Patent No.
	Assignee	Patent title	Filing Date	Issue Date
14.	Systagenix Wound	Absorbent multilayer	10538427	
	Management (US), Inc.;	hydrogel wound dressings	04/04/2006	
	Systagenix Wound			
	Management IP Co. B.V.			
15.	Systagenix Wound	Antioxidant wound	10560544	
	Management (US), Inc.;	dressing materials	12/14/2005	
	Systagenix Wound			
	Management IP Co. B.V.			
16.	Systagenix Wound	Wound dressing for the	10579897	
	Management (US), Inc.;	controlled release of	05/19/2006	
	Systagenix Wound	therapeutic agents		
	Management IP Co. B.V.		10.505000	
17.	Systagenix Wound	Medicated polyurethane	10587993	
	Management (US), Inc.;	foams	06/13/2007	
	Systagenix Wound			
18.	Management IP Co. B.V. Systagenix Wound	Methods for the treatment	11477307	
10.	Management (US), Inc.;	of wounds	06/29/2006	
	Systagenix Wound	of woulds	00/29/2000	
	Management IP Co. B.V.			
19.	Systagenix Wound	Diagnostic markers of	11516210	
17.	Management (US), Inc.;	wound infection II	09/06/2006	
	Systagenix Wound	Would infomit	05/00/2000	
	Management IP Co. B.V.			
20.	Systagenix Wound	Monitoring of wounds by	11575412	
	Management (US), Inc.;	measurement of protease	03/16/2007	
	Systagenix Wound	and protease inhibitor		
	Management IP Co. B.V.	levels in wound fluids		
21.	Systagenix Wound	Measurement of	11608906	
	Management (US), Inc.	cytoskeletal proteins and	12/11/2006	
		uses thereof in diagnosis,		
		prognosis and therapy		
22.	Systagenix Wound	Diagnosis and prognosis of	11608940	
	Management (US), Inc.;	wound infection by	12/11/2006	
	Systagenix Wound	measurement of a		
	Management IP Co. B.V.	phospholipase A2 in wound fluid		
23.	Systagenix Wound	Wound dressings for	11609964	
23.	Management (US), Inc.;	vacuum therapy	12/13/2006	
	Systagenix Wound	, acadin merapy	12/13/2000	
	Management IP Co. B.V.			
24.	Systagenix Wound	Method for detecting	10502882	
	Management (US), Inc.	microorganisms	02/23/2005	
25.	Systagenix Wound	Method for detecting	10543554	
	Management (US), Inc.	escherichia coli	04/28/2006	
26.	Systagenix Wound	Methods, peptides and	10576633	
	Management (US), Inc.	biosensors useful for	11/14/2006	
		detecting a broad spectrum		
		of bacteria		
27.	Systagenix Wound	Colorimetric substrates,	10576634	
	Management (US), Inc.	colorimetric sensors, and	04/05/2007	
		methods of use		

			Serial No.	Patent No.
	Assignee	Patent title	Filing Date	Issue Date
28.	Systagenix Wound	Device for detecting an	11814807	
	Management (US), Inc.;	enzyme in a sample	08/12/2008	
	Systagenix Wound			
	Management IP Co. B.V.			
29.	Systagenix Wound	Diagnostics and methods	12160610	
	Management (US), Inc.	for removal and detection	02/17/2009	
		of interferents		
30.	Systagenix Wound	Sample collection and	12279346	
	Management (US), Inc.	testing device with pivot	02/11/2009	
		arm		
31.	Systagenix Wound	Hydrogel wound dressings	12373619	
	Management (US), Inc.;	exhibiting reduced fiber	11/17/2009	
	Systagenix Wound	losses in use		
	Management IP Co. B.V.			
32.	Systagenix Wound	New wound dressing	12516487	
	Management (US), Inc.;	compositions	03/10/2010	
	Systagenix Wound			
22	Management IP Co. B.V.	77 1 1 11 1	12277071	
33.	Systagenix Wound	Hydrogel wound dressing	13377071	
2.4	Management (US), Inc. Systagenix Wound	for use with suction	05/04/2012 08280917	5447940
34.	Management (US), Inc.	Absorbable composite materials for use in the	08280917	09/05/1995
	Management (US), Inc.	treatment of periodontal	0//2//1994	09/03/1993
		disease		
35.	Systagenix Wound	Method of making	07971440	5571529
55.	Management (US), Inc.;	polyurethane foam	11/04/1992	11/05/1996
	Systagenix Wound	poryuremane roam	11/04/17/2	11/03/1990
	Management IP Co. B.V.			
36.	Systagenix Wound	Biopolymer composites	08437905	5660857
	Management (US), Inc.;		05/10/1995	08/26/1997
	Systagenix Wound			
	Management IP Co. B.V.			
37.	Systagenix Wound	Ointment for wound	08696443	5688522
	Management (US), Inc.;	treatment	08/13/1996	11/18/1997
	Systagenix Wound			
	Management IP Co. B.V.			
38.	Systagenix Wound	Sterile gel compositions	08462243	5693624
	Management (US), Inc.;	for wound treatment	06/05/1995	12/02/1997
	Systagenix Wound			
	Management IP Co. B.V.			
39.	Systagenix Wound	Heteromorphic sponges	08393963	5700476
4.0	Management (US), Inc.	containing active agents	02/24/1995	12/23/1997
40.	Systagenix Wound	Gel formulations	08539898	5705485
4.1	Management IP Co. B.V.	containing growth factors	10/06/1995	01/06/1998
41.	Systagenix Wound	Ointment for wound	08662103	5723144
	Management (US), Inc.;	treatment	06/14/1996	03/03/1998
	Systagenix Wound			
42	Management IP Co. B.V.	Water calable	00204024	5725912
42.	Systagenix Wound	Water soluble wound	08204024 02/28/1994	5735812 04/07/1998
	Management (US), Inc.; Systagenix Wound	dressing materials	02/20/1994	U 1 /U//1990
	Management IP Co. B.V.			
	ivianagement if Co. D. V.			

	Assignee	Patent title	Serial No. Filing Date	Patent No. Issue Date
43.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Wound dressing package	08293864 08/22/1994	5749842 05/12/1998
44.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Wound implant materials	08461791 06/05/1995	5766631 06/16/1998
45.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Composite surgical material	08280916 07/27/1994	5789465 08/04/1998
46.	Systagenix Wound Management (US), Inc.	Solvent dried polysaccharide sponges	08963106 11/03/1997	5888987 03/30/1999
47.	Systagenix Wound Management (US), Inc.	Wound diagnosis by quantitating cortisol in wound fluids	08928541 09/12/1997	5912114 06/15/1999
48.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Absorbent wound dressings	09067866 04/28/1998	5981822 11/09/1999
49.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Composite surgical material	08994276 12/19/1997	6001895 12/14/1999
50.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Composite surgical material	08995228 12/19/1997	6015844 01/18/2000
51.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Wound dressing comprising polyurethane foam	08987929 12/10/1997	6019996 02/01/2000
52.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Swellable wound dressing materials	08201522 02/25/1994	6022556 02/08/2000
53.	Avcor Health Care Products, Inc.; Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Bandage compression indicator	09192918 11/16/1998	6050967 04/18/2000
54.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Compositions for the treatment of chronic wounds	08992649 12/17/1997	6166084 12/26/2000
55.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Wound dressing comprising polyurethane foam	08436688 05/08/1995	6326410 12/04/2001
56.	Systagenix Wound Management (US), Inc.; Systagenix Wound	Bioresorbable aliginate derivatives	08993372 12/18/1997	6440940 08/27/2002

			Serial No.	Patent No.
	Assignee	Patent title	Filing Date	Issue Date
	Management IP Co. B.V.			
57.	Systagenix Wound	Polyurethane foams for use	09913181	6509388
	Management (US), Inc.;	in wound dressings	11/15/2001	01/21/2003
	Systagenix Wound			
	Management IP Co. B.V.			
58.	Systagenix Wound	Wound dressings having	09937039	6566577
	Management (US), Inc.;	low adherency	02/14/2002	05/20/2003
	Systagenix Wound			
	Management IP Co. B.V.			
59.	Systagenix Wound	Wound healing	08957654	6638909
	Management (US), Inc.	compositions containing	10/24/1997	10/28/2003
		alpha-1-antitrypsin		
60.	Systagenix Wound	Coated bioabsorbable	09142814	6713083
	Management (US), Inc.;	beads for wound treatment	05/21/1999	03/30/2004
	Systagenix Wound			
	Management IP Co. B.V.			
61.	Systagenix Wound	Device and method for	09427292	6915950
	Management (US), Inc.	chronic wound condition	10/26/1999	07/12/2005
		treatment		
62.	Systagenix Wound	Pain-sensitive therapeutic	10554375	7361634
	Management (US), Inc.;	wound dressings	10/25/2005	04/22/2008
	Systagenix Wound			
	Management IP Co. B.V.			
63.	Systagenix Wound	Fluid wound dressing	10532520	7538257
	Management (US), Inc.;	comprising partially cured	01/30/2006	05/26/2009
	Systagenix Wound	polyurethane		
	Management IP Co. B.V.	G: 1 1:00 :	11505055	7500504
64.	Systagenix Wound	Signal amplification using	11595275	7566564
<i>(</i>	Management (US), Inc.	a synthetic zymogen	11/09/2006	07/28/2009
65.	Systagenix Wound	Diagnostic test devices	10590248	7601546
	Management (US), Inc.;		04/26/2007	10/13/2009
	Systagenix Wound Management IB Co. B.V.			
66.	Management IP Co. B.V. Systagenix Wound	Controlled release	10497442	7732655
00.		therapeutic wound	03/03/2005	06/08/2010
	Management (US), Inc.; Systagenix Wound	dressings	03/03/2003	00/08/2010
	Management IP Co. B.V.	diessings		
67.	Systagenix Wound	Wound treatment device	10528742	7772454
07.	Management (US), Inc.;	would deather device	10/06/2005	08/10/2010
	Systagenix Wound		10/00/2003	00/10/2010
	Management IP Co. B.V.			
68.	Systagenix Wound	Diagnosis of clinical	10494507	7794925
	Management (US), Inc.;	infection of a wound	07/20/2004	09/14/2010
	Systagenix Wound			
	Management IP Co. B.V.			
69.	Systagenix Wound	Sample collection and	11913434	7955572
-	Management (US), Inc.;	testing device with swing	02/09/2009	06/07/2011
	Systagenix Wound	arm		
	Management IP Co. B.V.			
70.	Systagenix Wound	Diagnostic markers of	12450377	8012698
	Management (US), Inc.;	wound infection	03/10/2010	09/06/2011
	Systagenix Wound			

			Serial No.	Patent No.
	Assignee	Patent title	Filing Date	Issue Date
	Management IP Co. B.V.			
71.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Absorbent wound dressing containing a hydrogel layer	10496158 11/04/2004	8058499 11/15/2011
72.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Wound healing	11574442 10/01/2008	8063052 11/22/2011
73.	Systagenix Wound Management (US), Inc.	Pain-sensitive therapeutic wound dressing	12041955 03/04/2008	8067370 11/29/2011
74.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Layered materials for use as wound dressings	10445222 05/27/2003	8097272 01/17/2012
75.	Systagenix Wound Management (US), Inc.	Cationic anti-microbial peptides and methods of use thereof	10543523 04/20/2006	8124370 02/28/2012
76.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Antioxidant and antimicrobial wound dressing materials	10579850 05/17/2006	8124826 02/28/2012
77.	Systagenix Wound Management (US), Inc.	Method for detecting Escherichia coli	12894212 09/30/2010	8377651 02/19/2013
78.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Fluid wound dressing comprising partially cured polyurethane	12470620 05/22/2009	8481801 07/09/2013
79.	Systagenix Wound Management (US), Inc.; Systagenix Wound Management IP Co. B.V.	Marker of wound infection	11914884 08/25/2008	8491852 07/23/2013
80.	Systagenix Wound Management (US), Inc.	Cationic anti-microbial peptides and methods of use thereof	13335369 12/22/2011	8541193 09/24/2013

^{*}Inventor assignment to be filed with US PTO.

Trademarks:

				-
	6		Serial No.	Reg. No.
	Owner	Trademark	Filing Date	Reg. Date
1.	Systagenix Wound Management (US),	BIOSORB	8	
	Inc.		6	
			0	
			8	
			1	
			8	
			5	
			6	
			10/03/2013	
			ITU	
2.	Systagenix Wound Management (US),	FIBRAGRAN	85879557	
	Inc.		03/19/2013	
			ITU	
3.	Systagenix Wound Management (US),	WOUNDCHEK	85413291	4238917
	Inc.		09/01/2011	11/06/2012
4.	Systagenix Wound Management (US),	LET'S PROTECT	85066662	4195131
	Inc.		06/18/2010	08/21/2012
5.	Systagenix Wound Management (US),	LET'S TEST	85066658	4195130
	Inc.		06/18/2010	08/21/2012
6.	Systagenix Wound Management (US),	/%	85066656	4195129
0.	Inc.	l /65/20	06/18/2010	08/21/2012
	me.		00/10/2010	00/21/2012
	C	T DOWN THE A I	05066650	4107120
7.	Systagenix Wound Management (US),	LET'S HEAL	85066652	4195128
	Inc.	CYCCE A CENTRA	06/18/2010	08/21/2012
8.	Systagenix Wound Management (US),	SYSTAGENIX	85064731	4195125
	Inc.	1	06/16/2010	08/21/2012
9.	Systagenix Wound Management (US),	LET'S PROMOTE	85115182	4064367
	Inc.		08/25/2010	11/29/2011
10.	Systagenix Wound Management (US),	LET'S COMFORT	85075627	4050279
	Inc.		07/01/2010	11/01/2011
11.	Systagenix Wound Management (US),		85975453	4027162
	Inc.		06/18/2010	09/13/2011
12.	Systagenix Wound Management (US),	LET'S HEAL	85975436	4027160
12.	_• •	ELIBIDAL	06/18/2010	09/13/2011
13.	Inc. Systagenix Wound Management (US),	SYSTAGENIX	85975435	4027159
13.	_ * - * - * - * - * - * - * - * - * - *	SISIAGENIA	06/16/2010	09/13/2011
1.4	Inc. Systagenix Wound Management (US),	ADAPTIC TOUCH	85066651	4020415
14.	Inc.	ADAFTIC TOUCH	06/18/2010	08/30/2011
1.5	Systagenix Wound Management (US),	EACVITET DRECIGION		
15.		EASY LIFT PRECISION FILM	85066665	4010354 08/09/2011
1.0	Inc.		06/18/2010	
16.	Systagenix Wound Management (US),	SILVERCEL	78211665	3308037
17	Inc.	DDOMOCD AND DDICAGA	02/06/2003	10/09/2007
17.	Systagenix Wound Management (US),	PROMOGRAN PRISMA	78410947	3101756
10	Inc.	GYGE A GENTY	04/30/2004	06/06/2006
18.	Systagenix Wound Management (US),	SYSTAGENIX	77611717	4002816
4.7	Inc.		11/11/2008	07/26/2011
19.	Systagenix Wound Management (US),	LIQUALOCK	77953973	3971547

	_		Serial No.	Reg. No.
	Owner	Trademark	Filing Date	Reg. Date
	Inc.		03/09/2010	05/31/2011
20.	Systagenix Wound Management (US),	SYSTAGENIX WOUND	77694491	3850956
	Inc.	MANAGEMENT	03/19/2009	09/21/2010
21.	Systagenix Wound Management (US),	SYSTAGENIX WOUND	77578096	3861452
	Inc.	MANAGEMENT	09/24/2008	10/12/2010
22.	Systagenix Wound Management (US),	PROMOGRAN	76023540	2636375
	Inc.		04/13/2000	10/15/2002
23.	Systagenix Wound Management (US),	NU-GEL	74120215	1705750
	Inc.		12/03/1990	08/04/1992
24.	Systagenix Wound Management (US),	TIELLE	74688002	2022613
	Inc.		06/14/1995	12/10/1996
25.	Systagenix Wound Management (US),	FIBRACOL	74516835	1946084
	Inc.		04/25/1994	01/02/1996
26.	Systagenix Wound Management (US),	BIOCLUSIVE	73379898	1275730
	Inc.		08/13/1982	05/01/1984
27.	Systagenix Wound Management (US),	DYNA-FLEX	73379882	1277956
	Inc.		08/13/1982	05/15/1984
28.	Systagenix Wound Management (US),	NU-DERM	73767337	1547949
	Inc.		12/05/1988	07/18/1989
29.	Systagenix Wound Management (US),	ADAPTIC	73512181	1342006
	Inc.		12/05/1984	06/18/1985
30.	Systagenix Wound Management (US),	RELEASE	73308456	1260351
	Inc.		05/04/1981	12/06/1983
31.	Systagenix Wound Management (US),	TOPPER	71640743	0589006
	Inc.		01/14/1953	04/27/1954
32.	Systagenix Wound Management (US),	ADAPTIC	71225882	0213391
	Inc.		01/13/1926	05/25/1926

Copyright Registrations:

None.

PATENT REEL: 031508 FRAME: 0028

RECORDED: 10/29/2013